Epigenetics in Cancer

Dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible, and thus make a promising therapeutic target.

Epigenetics in Cancer Products Targets

Products for Epigenetics in Cancer - Page 9

Cat.No. Product Name Information/Activity
BCC3995 ME0328 ME0328 is a potent and selective ARTD3/PARP3 inhibitor with an IC50 of 0.89±0.28 μM.
BCN1025 Nicotinamide Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.
BCC2454 NU 1025 NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer drugs. NU1025 has anti-cancer and neuroprotective activity.
BCC2210 PJ34 hydrochloride PJ34 hydrochloride is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.
BCC2213 UPF 1069 UPF 1069 is a PARP inhibitor, with IC50s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.
BCC8013 C 21 Selective PRMT1 inhibitor
BCC8008 TC-E 5003 Selective PRMT1 inhibitor
BCC2459 DL-AP3 Phosphoserine phosphatase inhibitor
BCC2456 Calcineurin Autoinhibitory Peptide Selective calcineurin inhibitor
BCC2457 Calyculin A Calyculin A is a potent and cell-permeable protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) inhibitor with IC50s of 2 nM and 0.5-1 nM.